Cidara Therapeutics (CDTX) Stock Double as Merck Nears $9.2 Billion Acquisition

TLDR Cidara Therapeutics stock surged nearly 100% in premarket trading on Merck acquisition news Merck is paying $221.50 per share in cash, valuing Cidara at up to $9.2 billion The deal represents nearly triple Cidara’s previous $3.3 billion market capitalization Cidara’s CD388 flu prevention drug showed 76% efficacy in mid-stage trials The transaction could be [...]

The post Cidara Therapeutics (CDTX) Stock Double as Merck Nears $9.2 Billion Acquisition appeared first on Blockonomi.